EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Mallinckrodt's enterprise value is $-10 Mil.
Mallinckrodt's Revenue for the trailing twelve months (TTM) ended in Sep. 2024 was $1,488 Mil. Therefore, Mallinckrodt's EV-to-Revenue for today is -0.01.
The historical rank and industry rank for Mallinckrodt's EV-to-Revenue or its related term are showing as below:
MCKPF'
s EV-to-Revenue Range Over the Past 10 Years
Min: -0.01 Med: 1.35 Max: 2.42
Current: -0.01
During the past 13 years, the highest EV-to-Revenue of Mallinckrodt was 2.42. The lowest was -0.01. And the median was 1.35.
MCKPF's EV-to-Revenue is not ranked
in the Drug Manufacturers industry.
Industry Median: 2.43
vs MCKPF: -0.01
As of today (2025-06-26), Mallinckrodt's stock price is $0.12.
Mallinckrodt's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2024 was $75.51. Therefore, Mallinckrodt's PS Ratio for today is 0.00.
Mallinckrodt EV-to-Revenue Historical Data
The historical data trend for Mallinckrodt's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Mallinckrodt's EV-to-Revenue
For the Drug Manufacturers - Specialty & Generic subindustry, Mallinckrodt's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mallinckrodt's EV-to-Revenue Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Mallinckrodt's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Mallinckrodt's EV-to-Revenue falls into.
Mallinckrodt's current Enterprise Value is $-10 Mil.
Mallinckrodt's Revenue for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $1,488 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mallinckrodt's share price for today is $0.12.
Mallinckrodt's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $75.51.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mallinckrodt EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Mallinckrodt's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Mallinckrodt PLC develops, manufactures, markets, and distributes specialty pharmaceutical products and therapies. Its areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, nephrology, pulmonology, and ophthalmology; immunotherapy and neonatal respiratory critical care therapies; analgesics and gastrointestinal products. The company operates its business in two reportable segments namely Specialty Brands which include specialty pharmaceutical brands; and Specialty Generics which include niche specialty generic drugs and active pharmaceutical ingredients. It generates maximum revenue from the Specialty Brands segment. Geographically, it derives a majority of its revenue from the United States.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
MCKPF has been successfully added to your 